Notable Labs (NTBL) Stock Price, News & Analysis

Company Overview

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $0.24 to $0.31
• 50-Day Range: $0.24 to $0.64
• 52-Week Range: $0.22 to $4.24
• Volume: 2.11 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $2.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Notable Labs Stock Analysis - MarketRank™

Notable Labs scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Notable Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Notable Labs has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Notable Labs has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.71% of the float of Notable Labs has been sold short.

Short Interest Ratio / Days to Cover

Notable Labs has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Notable Labs has recently decreased by 19.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Notable Labs does not currently pay a dividend.

Dividend Growth

Notable Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.71% of the float of Notable Labs has been sold short.

Short Interest Ratio / Days to Cover

Notable Labs has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Notable Labs has recently decreased by 19.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Notable Labs has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.

Search Interest

Only 2 people have searched for NTBL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Notable Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Notable Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Notable Labs is held by insiders.

Percentage Held by Institutions

70.48% of the stock of Notable Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NTBL Stock Analysis - Frequently Asked Questions

How have NTBL shares performed this year?

Notable Labs' stock was trading at $1.89 at the start of the year. Since then, NTBL stock has decreased by 86.9% and is now trading at $0.2479.
View the best growth stocks for 2024 here.

How were Notable Labs' earnings last quarter?

Notable Labs, Ltd. (NASDAQ:NTBL) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.55) EPS for the quarter.

How do I buy shares of Notable Labs?

Shares of NTBL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Notable Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Notable Labs investors own include Algonquin Power & Utilities (AQN), LiveOne (LVO), Palatin Technologies (PTN), Frontier Group (ULCC), Adverum Biotechnologies (ADVM), Sirius XM (SIRI) and Clearside Biomedical (CLSD).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/23/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NTBL
• Previous Symbol: NASDAQ:NTBL
• CUSIP: N/A
• CIK: 1603207
• Web: www.vblrx.com
• Phone: (728) 993-5000
• Fax: 972-8993-5001
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +2,723.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,260,000.00
• Net Margins: N/A
• Pretax Margin: -3,368.05%
• Return on Equity: -80.81%
• Return on Assets: -62.86%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $310,000.00
• Price / Sales: 7.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.81 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 9,660,000
• Free Float: 9,544,000
• Market Cap: $2.39 million
• Optionable: No Data
• Beta: 0.98